GlassScriptPhysician profile
Myles B Howard
NPI 1831152941
$6,659.61
in general payments reported to CMS, 2019-2025
43 companies · $1,316 in 2025
The $1,316 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $455 · 2021: $687 · 2022: $1,086 · 2023: $1,327 · 2024: $1,498 · 2025: $1,316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,139.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $741.51 | 2019-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Abbvie INC. | $610.73 | 2020-2025 | |
| Abbott Laboratories | $607.50 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $454.49 | 2019-2025 | |
| Novo Nordisk INC | $356.06 | 2021-2025 | Rybelsus, Ozempic |
| Shield Therapeutics INC | $354.72 | 2023-2025 | Accrufer |
| Gilead Sciences, INC. | $278.63 | 2021-2025 | Yeztugo |
| Bayer Healthcare Pharmaceuticals INC. | $247.89 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $241.73 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $211.44 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $207.25 | 2023-2024 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.51 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Orexo US, INC. | $185.11 | 2019-2025 | Zubsolv |
| Exact Sciences Corporation | $150.94 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $145.67 | 2022-2025 | Rexulti |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Myles Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.